CureVac NV (NASDAQ:CVAC)
| 111.20 Delayed Data As of Apr 20 |  -2.22 / -1.96%Today’s Change | 36.15 Today|||52-Week Range 151.80 | +37.17% Year-to-Date |
Latest CVAC News | Press Releases
| 2 Reasons This COVID Vaccine Latecomer Could Gain Major Market Share 6:30am / MotleyFool.com - Paid Partner Content | CureVac (CVAC) Q4 2020 Earnings Call Transcript Apr 15 / MotleyFool.com - Paid Partner Content |
| Novartis (NVS) Collaborates with Roche for API of RA Drug Actemra Apr 16 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 113.00 |
| Today’s open | 109.94 |
| Day’s range | 106.58 - 111.27 |
| Volume | 1,038,693 |
| Average volume (3 months) | 850,112 |
| Market cap | $21.0B |
Data as of 4:00pm ET, 04/20/2021
Growth & Valuation
| Earnings growth (last year) | -33.01% |
| Earnings growth (this year) | -- |
| Earnings growth (next 5 years) | -113.50% |
| Revenue growth (last year) | +28.37% |
| P/E ratio | NM |
| Price/Sales | -- |
| Price/Book | -- |
Competitors
| No competitors data available. |
Financials
| Last reporting date | -- |
| EPS forecast (this quarter) | -$0.52 |
| Annual revenue (last year) | $19.5M |
| Annual profit (last year) | -$111.8M |
| Net profit margin | -573.46% |
Profile
Sector Health Technology |
Industry Pharmaceuticals: Major |
No executives to display |
Corporate headquarters --, -- |
Forecasts
